CD22 and lymphoma: Since 223Ra cannot be reliably chelated and then coupled to binding vector molecules, its parent nuclide thorium-227, with a half-life of 18.7 days, was used in a first human clinical trial for targeted alpha therapy with monoclonal antibodies against CD22 in lymphomas.